Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Developmental Therapeutics Implications of Next-Generation Sequencing in Human Herpesvirus 8-Negative Castleman Disease.

Zhou XA, Chae YK, Giles FJ.

JAMA Dermatol. 2017 May 1;153(5):381-382. doi: 10.1001/jamadermatol.2016.5555. No abstract available.

PMID:
28241212
2.

Epidemiology of Castleman Disease.

Simpson D.

Hematol Oncol Clin North Am. 2018 Feb;32(1):1-10. doi: 10.1016/j.hoc.2017.09.001. Review.

PMID:
29157611
3.

EBV+ HHV-8+ Multicentric Castleman Disease With Plasmablastic Aggregates in an HIV+ Man: An Evolving Clinicopathologic Entity.

Shivane A, Pearce A, Khatib N, Smith MEF.

Int J Surg Pathol. 2018 Jun;26(4):338-341. doi: 10.1177/1066896917745584. Epub 2017 Dec 3.

PMID:
29198143
4.

Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease.

London J, Boutboul D, Agbalika F, Coppo P, Veyradier A, Gérard L, Oksenhendler E, Azoulay E, Galicier L.

Br J Haematol. 2017 Aug;178(3):486-488. doi: 10.1111/bjh.14152. Epub 2016 May 25. No abstract available.

PMID:
27221364
5.

Castleman Disease Pathogenesis.

Fajgenbaum DC, Shilling D.

Hematol Oncol Clin North Am. 2018 Feb;32(1):11-21. doi: 10.1016/j.hoc.2017.09.002. Review.

PMID:
29157613
6.

Next-Generation Sequencing in the Understanding of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Biology.

Strahan R, Uppal T, Verma SC.

Viruses. 2016 Mar 31;8(4):92. doi: 10.3390/v8040092. Review.

7.

Human Herpesvirus Type 8-positive Multicentric Castleman Disease.

Melikyan AL, Egorova EK, Julhakyan HL, Kovrigina AL, Savchenko VG.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S159-65. doi: 10.1016/j.clml.2016.03.009. Epub 2016 Apr 1.

PMID:
27133959
8.

Kaposi's Sarcoma-Associated Herpesvirus: Epidemiology and Molecular Biology.

Li S, Bai L, Dong J, Sun R, Lan K.

Adv Exp Med Biol. 2017;1018:91-127. doi: 10.1007/978-981-10-5765-6_7. Review.

PMID:
29052134
9.

Use of plasma human herpesvirus-8 viral load measurement: evaluation of practice in three UK HIV treatment centres.

Nugent DB, Webster D, Mabayoje D, Chung E, El Bouzidi K, O'Sullivan A, Ainsworth J, Miller RF.

Int J STD AIDS. 2017 Feb;28(2):188-191. doi: 10.1177/0956462416676031. Epub 2016 Oct 23.

PMID:
28120699
10.

iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease.

Sbihi Z, Dossier A, Boutboul D, Galicier L, Parizot C, Emarre A, Hoareau B, Dupin N, Marcelin AG, Oudin A, Fieschi C, Agbalika F, Autran B, Oksenhendler E, Carcelain G.

Blood. 2017 Feb 16;129(7):855-865. doi: 10.1182/blood-2016-06-719716. Epub 2016 Nov 9.

PMID:
28060720
11.

Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, Uldrick TS, Yarchoan R, Medeiros LJ, Li Y, Fajgenbaum DC, Young KH.

Blood. 2017 Mar 23;129(12):1658-1668. doi: 10.1182/blood-2016-11-748855. Epub 2017 Jan 18.

12.

Diagnosis and management of Castleman disease.

Soumerai JD, Sohani AR, Abramson JS.

Cancer Control. 2014 Oct;21(4):266-78. Review.

PMID:
25310208
13.

Pathology of Castleman Disease.

Wu D, Lim MS, Jaffe ES.

Hematol Oncol Clin North Am. 2018 Feb;32(1):37-52. doi: 10.1016/j.hoc.2017.09.004. Review.

PMID:
29157618
14.

Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report.

Basnayake BMDB, Wazil AWM, Kannangara T, Ratnatunga NVI, Hewamana S, Ameer AM.

J Med Case Rep. 2017 May 14;11(1):135. doi: 10.1186/s13256-017-1294-3.

15.

JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.

Patel M, Ikeda S, Pilat SR, Kurzrock R.

JAMA Dermatol. 2017 May 1;153(5):449-452. doi: 10.1001/jamadermatol.2016.5554.

16.

Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients.

Pria AD, Pinato D, Roe J, Naresh K, Nelson M, Bower M.

Blood. 2017 Apr 13;129(15):2143-2147. doi: 10.1182/blood-2016-10-747477. Epub 2017 Jan 31.

17.

Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.

Kaplan LD.

Hematology Am Soc Hematol Educ Program. 2013;2013:103-8. doi: 10.1182/asheducation-2013.1.103. Review.

PMID:
24319170
18.

The full spectrum of Castleman disease: 273 patients studied over 20 years.

Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, Vercellino L, Meignin V, Gérard L, Galicier L.

Br J Haematol. 2018 Jan;180(2):206-216. doi: 10.1111/bjh.15019. Epub 2017 Nov 16.

PMID:
29143319
19.

Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?

Abid MB, Peck R, Abid MA, Al-Sakkaf W, Zhang Y, Dunnill GS, Staines K, Sequeiros IM, Lowry L.

Hematol Oncol. 2018 Feb;36(1):320-323. doi: 10.1002/hon.2420. Epub 2017 Apr 11.

PMID:
28401573
20.

KSHV 2.0: a comprehensive annotation of the Kaposi's sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features.

Arias C, Weisburd B, Stern-Ginossar N, Mercier A, Madrid AS, Bellare P, Holdorf M, Weissman JS, Ganem D.

PLoS Pathog. 2014 Jan;10(1):e1003847. doi: 10.1371/journal.ppat.1003847. Epub 2014 Jan 16.

Supplemental Content

Support Center